is in compliance with the HONcode
Certificate validity: 13 Jun 2013 - Jun 2015
The process of re-certification for 2017-2018 has been launched, however we do not have any feedback from the webmaster about the changes requested during the re-evaluation.
www.eviq.org.au Visit website
13 Jun 2013
13 Jun 2013 - Jun 2015
06 Apr 2017
See the HONcode seal on the site
The content below is a sample of the content identified at a specific date by the HONcode team that justifies the respect of the eight ethical principles.
The eviQ Team
Aimee Kim - Haematology/HPCT/Pharmacy
Aisling Kelly - eviQ Quality Manager
Cassandra O'Brien - Cancer Genetics/Medical Oncology/Nursing
Catherine Westaway - Project Officer
Gemma Dyer - Cancer Genetics/HPCT
Jill Graham - Radiation Oncology
Julia Shingleton - eviQ Content Manager (maternity leave)
Liesel Byrne - Medical Oncology/Pharmacy (maternity leave)
Lisa King - Medical Oncology (Lung, Head & Neck, Gynaecological, Urogenital, Sarcoma)
Lydia Loke - Medical Oncology (Breast, Colorectal, Upper GI, Melanoma, Neurological)
Marie Brand - Patient Information
Patricia Ryan - Haematology/HPCT/Nursing
Pippa Rendel - A/Content Manager
Rebecca Maher - Content Author/Pharmacy
Shelley Rushton - Program Manager
(21 Jan 2016) - Link
The Information is not intended to replicate or replace the knowledge, skills and experience of trained oncology health professionals, nor is it a substitute for clinical judgement and advice. This site is not designed to replace the relationship that exists between a patient and their physician or other qualified health professional. Patients should evaluate the Information together with their health professional.
(21 Jan 2016) - Link
An individual’s right to privacy as established under the Privacy and Personal Information Protection Act 1998 and the Health Records and Information Privacy Act 2002 is respected by the Cancer Institute NSW and protected. The Cancer Institute NSW does not allow the publication of information that may identify individuals, or might potentially identify them.
Links to other websites, external to the Cancer Institute NSW, are sometimes included in web pages for the convenience of website users, but the Cancer Institute NSW does not have any responsibility for the privacy practices of third party websites linked to the Cancer Institute NSW website.
Is information collected about your website visit?
When you look at pages on this website, our computers automatically record information that identifies, for each page accessed:
the IP (Internet Protocol) address of the machine which has accessed it,
your top-level domain name (for example .com, .gov, .au, .uk etc), the address of your server,
the date and time of your visit to the site,
the pages accessed and documents downloaded,
the name of the file or the words you searched, and
your name and other registration details (if applicable),
the previous site visited, and
the type of browser and operating system you used to access our site.
How do we use the information collected?
The information collected during each visit is aggregated with similar logged information and published in reports in order for the Cancer Institute NSW to identify patterns of usage of the site. This will assist us to improve this website and the eviQ program and is also used for the purposes of the Cancer Institute's functions under the Cancer Institute NSW Act 2003.
The Cancer Institute NSW also creates a de-identified version of this information, with your access to this website identified by the State or region listed in your registration details (and not by your or your hospital's registration details or other personal information).
The Cancer Institute NSW may use this de-identified information for research purposes, and may disclose this de-identified information to third parties, including publication of de-identified information in peer reviewed journals and other publications.
Personal information or information that identifies individual hospitals, machines, or groupings of addresses will not be published or disclosed without your consent, unless such disclosure is required by law.
Confirmation of registration details
In order to assist in the continuous quality improvement of the information on the website, you are required to:
review and confirm your registration details every year; and
complete an annual feedback survey.
You will be prompted to both review and confirm your registration details and complete the survey within three (3) calendar months from the date of notification. A failure to complete the survey within the required three-month period will result in the automatic closure of your account.
What does the Cancer Institute NSW do with personal information provided in feedback?
Email addresses provided to this website will only be used to respond to enquiries and will not be added to mailing lists, or disclosed to any other party without the user’s consent, unless the Cancer Institute NSW is required to disclose that information by law. Personal information will be kept in safe custody, sufficient to prevent unauthorised access, and will be properly handled to ensure its safety, integrity and confidentiality.
(21 Jan 2016) - Link
The data displayed correspond to only one of the selected samples.
Pfreundschuh, M., L. Trumper, M. Kloess, et al. 2004. "Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL." Blood 104(3):634-641.
Peyrade, F., F. Jardin, C. Thieblemont, et al. 2011. "Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial." Lancet Oncol 12(5):460-468.
Thieblemont, C., A. Grossoeuvre, R. Houot, et al. 2008. "Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome." Ann Oncol 19(4):774-779.
d'Amore, F., H. Brincker, B. E. Christensen, et al. 1992. "Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group." Ann Oncol 3(5):379-386.
Merli, F., S. Luminari, G. Rossi, et al. 2012. "Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi." Leuk Lymphoma 53(4):581-588.
Meguro, A., K. Ozaki, K. Sato, et al. 2012. "Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older." Leuk Lymphoma 53(1):43-49.
Italiano, A., F. Jardin, F. Peyrade, et al. 2005. "Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old." Haematologica 90(9):1281-1283.
Bairey, O., O. Benjamini, D. Blickstein, et al. 2006. "Non-Hodgkin's lymphoma in patients 80 years of age or older." Ann Oncol 17(6):928-934.
Pettengell, R., M. Schwenkglenks and A. Bosly. 2008. "Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy." Ann Hematol 87(5):429-430.
Kwak, L. W., J. Halpern, R. A. Olshen, et al. 1990. "Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis." J Clin Oncol 8(6):963-977.
Pfreundschuh, M. Zeynalova, S. Zwick, C., 2014. "Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas; the SEXIE-R-CHOP-14 trial of the DAHNHL." Clinical advances in haematology & oncology: H&O. 2014;12(8 Supplement 16):8-9
(21 Jan 2016) - Link
Approved: 07 Jan 2016 Last Modified: 07 Jan 2016 Review Due: 31 Dec 2018
(21 Jan 2016) - Link
The content of this certificate has been collected by the HON Foundation and may not be used without HON's express consent.
The Health On the Net (HON) certificate guarantees that this website complies with the eight principles of the HON Foundation's Code of Conduct at the date indicated above. The persons responsible for the site commit to maintaining its compliance with the HONcode principles for the duration of the site’s certification.
However, despite the complaint system that has been put in place and the periodic review and automatic monitoring of certified sites to ensure maximum compliance with the HONcode ethical principles, it is impossible to eliminate all risks of incoherence that may appear.
Under no circumstances shall the HON Foundation and/or its partner(s) be held liable for any damages resulting from the use or the inability to use HONcode-certified websites. Similarly, the HON Foundation and/or its partner(s) shall not be held liable for the content of such certified websites or any other website accessible via a hypertext link or through third-party information.
Those responsible for the certified website are responsible for the content of the website unless otherwise provided by law.More information about the HONcode?
Request HONcode certification!HONcode certification request
Search HONcode-certified websites:
The HONcode toolbar is easy to download and add to your Web browser. It connects in real time to the HON server to verify the certification status of health and medical websites. It does not collect any personal information and contains no spyware or other hidden functions.